Table 2.

Baseline characteristics of patients with V600E versus V600K metastatic melanoma (immunotherapy cohort)

CharacteristicsV600E (n = 84)V600K (n = 19)P value
Age (years)
 Median5161.50.0358
Gender (N, %)0.001
 Female41 (49%)3 (16%)
 Male43 (51%)16 (84%)
AJCC stagea (N, %)0.7571
 IIIC–M1b18 (21%)3 (16%)
 M1c66 (79%)16 (84%)
LDH (N, %)0.1195
 Normal49 (58%)15 (79%)
 Elevated35 (42%)4 (21%)
ECOG (N, %)0.2037
 042 (50%)13 (68%)
 ≥142 (50%)6 (32%)
Prior MAPKi (N, %)0.8042
 No47 (56%)11 (58%)
 Yes37 (44%)8 (42%)
PD1 therapy (N, %)0.0229
 Nivolumab222
 Pembrolizumab6217
  • aAJCC v7 anatomic staging, excluding LDH and brain metastases.